Theravance Biopharma Inc Fundamental Analysis
Theravance Biopharma Inc (TBPH) shows moderate financial fundamentals with a PE ratio of 7.44, profit margin of 1.04%, and ROE of 43.85%. The company generates $0.1B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 87.9/100 based on profitability, valuation, growth, and balance sheet metrics. The B+ grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze TBPH's fundamental strength across five key dimensions:
Efficiency Score
ExcellentTBPH demonstrates superior asset utilization.
Valuation Score
ExcellentTBPH trades at attractive valuation levels.
Growth Score
WeakTBPH faces weak or negative growth trends.
Financial Health Score
ExcellentTBPH maintains a strong and stable balance sheet.
Profitability Score
ModerateTBPH maintains healthy but balanced margins.
Key Financial Metrics
Is TBPH Expensive or Cheap?
P/E Ratio
TBPH trades at 7.44 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, TBPH's PEG of 0.00 indicates potential undervaluation.
Price to Book
The market values Theravance Biopharma Inc at 2.97 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 7.64 times EBITDA. This is generally considered low.
How Well Does TBPH Make Money?
Net Profit Margin
For every $100 in sales, Theravance Biopharma Inc keeps $1.04 as profit after all expenses.
Operating Margin
Core operations generate 0.08 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $43.85 in profit for every $100 of shareholder equity.
ROA
Theravance Biopharma Inc generates $24.25 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Theravance Biopharma Inc generates strong operating cash flow of $271.66M, reflecting robust business health.
Free Cash Flow
Theravance Biopharma Inc generates strong free cash flow of $271.62M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $5.24 in free cash annually.
FCF Yield
TBPH converts 30.77% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
7.44
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.004
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.97
vs 25 benchmark
P/S Ratio
Price to sales ratio
7.96
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.25
vs 25 benchmark
Current Ratio
Current assets to current liabilities
13.14
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.44
vs 25 benchmark
ROA
Return on assets percentage
0.24
vs 25 benchmark
ROCE
Return on capital employed
0.00
vs 25 benchmark
How TBPH Stacks Against Its Sector Peers
| Metric | TBPH Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 7.44 | 29.15 | Better (Cheaper) |
| ROE | 43.85% | 438.00% | Weak |
| Net Margin | 104.34% | -11409.00% (disorted) | Strong |
| Debt/Equity | 0.25 | 0.78 | Strong (Low Leverage) |
| Current Ratio | 13.14 | 5.14 | Strong Liquidity |
| ROA | 24.25% | -23.00% (disorted) | Strong |
TBPH outperforms its industry in 5 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Theravance Biopharma Inc's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation